Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study)

被引:32
作者
Aroda, V. R. [1 ]
Bailey, T. S. [2 ]
Cariou, B. [3 ]
Kumar, S. [4 ,5 ]
Leiter, L. A. [6 ,7 ]
Raskin, P. [8 ]
Zacho, J. [9 ]
Andersen, T. H. [9 ]
Philis-Tsimikas, A. [10 ]
机构
[1] MedStar Hlth Res Inst, 6525 Belcrest Rd,Suite 700, Hyattsville, MD 20782 USA
[2] AMCR Inst Inc, Escondido, CA USA
[3] CHU Nantes, Inst Thorax, Dept Endocrinol, F-44035 Nantes 01, France
[4] Univ Hosp Coventry, WISDEM Ctr, Coventry, W Midlands, England
[5] Univ Hosp Warwickshire, WISDEM Ctr, Coventry, W Midlands, England
[6] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[7] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada
[8] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[9] Novo Nordisk AS, Soborg, Denmark
[10] Scripps Whittier Diabet Inst, San Diego, CA USA
关键词
GLP-1; glycaemic control; type; 2; diabetes; TO-TARGET TRIAL; IMPROVES GLYCEMIC CONTROL; OPEN-LABEL; PARALLEL-GROUP; NAIVE PATIENTS; BASAL INSULIN; GLARGINE; 26-WEEK; EFFICACY; SAFETY;
D O I
10.1111/dom.12661
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To evaluate the efficacy and safety of adding insulin degludec (IDeg) to treatment in patients with type 2 diabetes receiving liraglutide and metformin and qualifying for treatment intensification because of inadequate glycaemic control. Methods: In this 26-week, double-blind trial, patients who still had inadequate glycaemic control after a 15-week run-in period with initiation and dose escalation of liraglutide to 1.8mg in combination with metformin (>= 1500 mg) were randomized to addition of once-daily IDeg ('IDeg add-on to liraglutide' arm; n= 174) or placebo ('placebo add-on to liraglutide' arm; n= 172), with dosing of both IDeg and placebo based on titration guidelines. Results: At 26 weeks, the mean change in glycated haemoglobin level was greater in the IDeg add-on to liraglutide arm (-1.04%) than in the placebo add-on to liraglutide arm (-0.16%; p< 0.0001). Similarly, the mean fasting plasma glucose reduction was greater, and self-measured plasma glucose values were lower at all eight time points, with IDeg add-on versus placebo add-on (both p< 0.0001). At 26 weeks, the IDeg dose was 51 U (0.54 U/kg). During the run-in period with liraglutide, body weight decreased by similar to 3 kg in both groups. After 26 weeks, the mean change was + 2.0 kg (IDeg add-on to liraglutide) and -1.3 kg (placebo add-on to liraglutide). Confirmed hypoglycaemia rates were low in both groups, although higher with IDeg than with placebo (0.57 vs. 0.12 episodes/patient-years of exposure; p= 0.0002). Nocturnal confirmed hypoglycaemia was infrequent in both groups, with no episodes of severe hypoglycaemia, and no marked differences in adverse events with either treatment approach. Conclusion: The addition of liraglutide and IDeg to patients sub-optimally treated with metformin and liraglutide and requiring treatment intensification was found to be effective and well-tolerated.
引用
收藏
页码:663 / 670
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 2015, VICTOZA 6 MG ML SOLU
[2]   Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature [J].
Balena, R. ;
Hensley, I. E. ;
Miller, S. ;
Barnett, A. H. .
DIABETES OBESITY & METABOLISM, 2013, 15 (06) :485-502
[3]   An overview of the pharmacokinetics, efficacy and safety of liraglutide [J].
Bode, Bruce .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (01) :27-42
[4]   Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents [J].
Buse, John B. ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Chang, Cheng-Tao ;
Xu, Yizhen ;
Blonde, Lawrence ;
Rosenstock, Julio .
DIABETES CARE, 2010, 33 (06) :1300-1303
[5]   Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].
Buse, John B. ;
Rosenstock, Julio ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Brett, Jason H. ;
Zychma, Marcin ;
Blonde, Lawrence .
LANCET, 2009, 374 (9683) :39-47
[6]   Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets [J].
DeVries, J. Hans ;
Bain, Stephen C. ;
Rodbard, Helena W. ;
Seufert, Jochen ;
D'Alessio, David ;
Thomsen, Anne B. ;
Zychma, Marcin ;
Rosenstock, Julio .
DIABETES CARE, 2012, 35 (07) :1446-1454
[7]  
FDA, 2008, GUID IND DIAB MELL D
[8]   Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [J].
Garber, Alan ;
Henry, Robert ;
Ratner, Robert ;
Garcia-Hernandez, Pedro A. ;
Rodriguez-Pattzi, Hiromi ;
Olvera-Alvarez, Israel ;
Hale, Paula M. ;
Zdravkovic, Milan ;
Bode, Bruce .
LANCET, 2009, 373 (9662) :473-481
[9]   AACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2015 [J].
Garber, Alan J. ;
Abrahamson, Martin J. ;
Barzilay, Joshua I. ;
Blonde, Lawrence ;
Bloomgarden, Zachary T. ;
Bush, Michael A. ;
Dagogo-Jack, Samuel ;
Davidson, Michael B. ;
Einhorn, Daniel ;
Garber, Jeffrey R. ;
Garvey, W. Timothy ;
Grunberger, George ;
Handelsman, Yehuda ;
Hirsch, Irl B. ;
Jellinger, Paul S. ;
McGill, Janet B. ;
Mechanick, Jeffrey I. ;
Rosenblit, Paul D. ;
Umpierrez, Guillermo ;
Davidson, Michael H. .
ENDOCRINE PRACTICE, 2015, 21 (04) :438-447
[10]   Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial [J].
Garber, Alan J. ;
King, Allen B. ;
Del Prato, Stefano ;
Sreenan, Seamus ;
Balci, Mustafa K. ;
Munoz-Torres, Manuel ;
Rosenstock, Julio ;
Endahl, Lars A. ;
Francisco, Ann Marie Ocampo ;
Hollander, Priscilla .
LANCET, 2012, 379 (9825) :1498-1507